R&D Pipeline

CCrest Laboratories is developing novel solutions for combating the Anti-Microbial Resistance crisis.

At CCrest Laboratories, in collaboration with our partners such as MHCombiotic, we are dedicated to pioneering solutions in the battle against Anti-Microbial Resistance, a critical global health threat.

Our R&D pipeline reflects our commitment to addressing the urgent challenges of Anti-Microbial Resistance across multiple fronts.

Our dedication to research and innovation drives us toward achieving better health outcomes and advancing the field of antimicrobial treatment.

By developing innovative solutions for wound care, respiratory infections, and bovine mastitis, CCrest and its partners are at the forefront of efforts to mitigate the impacts of this global health crisis.

Wound Care and Biofilm-Related Infections

Biofilms, complex communities of bacteria that adhere to wound surfaces, present a significant challenge in wound management. These bacterial communities are notably resistant to conventional treatments, complicating the healing process and increasing the risk of chronic infections.

Such wound infections not only degrade the quality of life for patients and their families but also lead to prolonged hospital stays, escalated healthcare costs, and elevated risks of morbidity and mortality.

Innovation in Treatment

CCrest and its partners have developed Combiotic, a cutting-edge antimicrobial formulation designed to tackle the multifaceted issues associated with wound infections.

Combiotic offers several advantages, including reduced toxicity, enhanced antimicrobial and antibiofilm effectiveness, minimized risk of future resistance, and successful eradication of chronic wound infections.

Respiratory Infections

Respiratory infections rank among the leading causes of mortality worldwide, as stated by the World Health Organization (WHO).

Vulnerable groups such as infants, the elderly, individuals with compromised immune systems, and those with pre-existing health conditions face heightened risks of severe complications from these infections.

Research Focus

We are exploring the therapeutic potential of Combiotic in treating respiratory infections, leveraging its broad-spectrum properties—antibacterial, antibiofilm, antioxidant, and anti-inflammatory—to offer a multifaceted approach to combatting these pervasive health threats.

Bovine Mastitis

Bovine mastitis, a prevalent condition in dairy cattle, incurs significant economic losses globally, amounting to billions annually. Traditional antibiotic treatments often fall short due to resistance issues and the complex nature of the disease.

Solution Development

CCrest and its partners are advancing a novel treatment approach with Combiotic, aiming to address the challenges posed by bovine mastitis effectively. Through rigorous preclinical trials, involving over 18,000 tests to assess its efficacy and safety, Combiotic is well-positioned for the next phases of development, promising a significant advancement in managing this widespread agricultural problem.